



Oraverse consent

Oraverse (phentolamine mesylate) is a medicine that reverses the effects of local anesthesia. It is approved by the FDA for pediatric patients who are at least three years old and 33 pounds. Oraverse is administered in the same way that the local anesthesia is administered, after the treatment is completed. Patients return to normal sensation over two times faster with Oraverse.

Benefits: Children are at high risk for self-injury while numb from accidental biting of their soft tissue. Oraverse decreases the risk of accidental self-injury since the numb feeling disappears faster. Oraverse also allows normal facial functions (smiling, talking, drinking) to return more quickly, and drooling is minimized.

Risks: There are minimal risks with appropriate dosing. The most common adverse reaction is injection-site pain. Headaches and faster heart rate has also been reported at higher doses.

Oraverse is not covered by dental insurance. Eastshore Pediatric Dental Group charges a nominal fee of \$15 to cover the costs associated with supplying Oraverse.

Consent: I have read the above information, understand the risks, benefits, and costs, and have had the opportunity to ask questions. I consent to the use of Oraverse for my child.

Child's name: _____

Parent/Guardian name: _____ Signature: _____

Date: _____